|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AVI BioPharma Inc., of Portland, Ore., reported in this month's issue of Clinical Cancer Research results of a Phase II trial testing its Avicine cancer vaccine in patients with late-stage colorectal cancer. In the randomized, multicenter, 77-patient study, anti-hCG antibodies were detected in 56 patients. An intention-to-treat analysis of all vaccinated patients showed a median survival of 34 weeks. Patients who developed higher anti-hCG antibody levels exhibited a median survival of 45 weeks. Subsequent analysis showed that patients who produced the antibodies to two segments of the hCG peptide had a median survival of 66 weeks.
Axonyx Inc., of New York, ...